[go: up one dir, main page]

SMT201800468T1 - Mutante del polipeptide fattore ix, suoi usi e metodo per la sua produzione - Google Patents

Mutante del polipeptide fattore ix, suoi usi e metodo per la sua produzione

Info

Publication number
SMT201800468T1
SMT201800468T1 SM20180468T SMT201800468T SMT201800468T1 SM T201800468 T1 SMT201800468 T1 SM T201800468T1 SM 20180468 T SM20180468 T SM 20180468T SM T201800468 T SMT201800468 T SM T201800468T SM T201800468 T1 SMT201800468 T1 SM T201800468T1
Authority
SM
San Marino
Prior art keywords
factor
production
polypeptide mutant
mutant
polypeptide
Prior art date
Application number
SM20180468T
Other languages
English (en)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201800468(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B V filed Critical Uniqure Biopharma B V
Publication of SMT201800468T1 publication Critical patent/SMT201800468T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SM20180468T 2008-09-15 2009-09-15 Mutante del polipeptide fattore ix, suoi usi e metodo per la sua produzione SMT201800468T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
EP09748260.8A EP2337849B1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number Publication Date
SMT201800468T1 true SMT201800468T1 (it) 2018-11-09

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20230084T SMT202300084T1 (it) 2008-09-15 2009-09-15 Mutante del polipeptide del fattore ix, suoi usi ed un metodo per la sua produzione
SM20180468T SMT201800468T1 (it) 2008-09-15 2009-09-15 Mutante del polipeptide fattore ix, suoi usi e metodo per la sua produzione

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20230084T SMT202300084T1 (it) 2008-09-15 2009-09-15 Mutante del polipeptide del fattore ix, suoi usi ed un metodo per la sua produzione

Country Status (19)

Country Link
US (13) US9249405B2 (it)
EP (5) EP3252157A1 (it)
CA (1) CA2737094C (it)
CY (2) CY1125885T1 (it)
DK (2) DK2337849T3 (it)
ES (3) ES2985035T3 (it)
FI (5) FI3581650T3 (it)
FR (4) FR23C1028I1 (it)
HK (1) HK1244507A1 (it)
HR (2) HRP20230259T1 (it)
HU (6) HUE061345T2 (it)
LT (5) LT3581650T (it)
NO (2) NO2023029I1 (it)
PL (3) PL2337849T3 (it)
PT (1) PT3581650T (it)
SI (1) SI3581650T1 (it)
SM (2) SMT202300084T1 (it)
TR (1) TR201813067T4 (it)
WO (1) WO2010029178A1 (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249405B2 (en) 2008-09-15 2016-02-02 Paolo Simioni Factor IX polypeptide mutant, its uses and a method for its production
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
PL2956477T5 (pl) 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CA2990193A1 (en) 2015-06-23 2016-12-29 The Children's Hospital Of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
CN106497949A (zh) * 2016-10-14 2017-03-15 上海交通大学医学院附属瑞金医院 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
MX2019013836A (es) 2017-05-22 2020-01-30 Baxalta Inc Vectores virales que codifican variantes del factor de coagulacion ix (fix) recombinantes con mayor expresion para la terapia genica de hemofilia b.
IL271957B2 (en) 2017-07-10 2024-02-01 Uniqure Ip Bv Means and methods for AAV-based gene therapy
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3790627A2 (en) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
JP2021523198A (ja) 2018-05-14 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド 幼若対象におけるａａｖベクターの安定的発現
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CN112739818A (zh) * 2018-08-20 2021-04-30 Ucl商业有限责任公司 编码因子ix的核苷酸
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
EP3867380A2 (en) 2018-10-18 2021-08-25 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
EP4362971A1 (en) * 2021-07-01 2024-05-08 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety
WO2025022005A1 (en) * 2023-07-26 2025-01-30 Le Quellec Sandra Intranasal administration of factor ix polypeptides

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107278B1 (en) 1982-08-04 1989-11-15 National Research Development Corporation Molecular cloning of the gene for human anti-haemophilic factor ix
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
JP3553970B2 (ja) 1996-06-11 2004-08-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 組換え血液凝固プロテアーゼ
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
CA2280700A1 (en) 1997-02-14 1998-08-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6610906B1 (en) 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
WO2002004544A2 (en) 2000-07-06 2002-01-17 Guilford Pharmaceuticals Polymers and polymerization processes
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
WO2003089612A2 (en) 2002-04-17 2003-10-30 University Of Florida Research Foundation, Inc. IMPROVED rAAV VECTORS
JP5376747B2 (ja) 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
MX2007001294A (es) 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
EP1627771B1 (de) 2004-08-19 2008-10-15 Gerd Bär Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
DK2438931T3 (da) 2004-09-22 2013-12-02 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CN101124328A (zh) 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
ES2611608T3 (es) 2005-10-21 2017-05-09 Catalyst Biosciences, Inc. Proteasas modificadas que inhiben la activación del complemento
US20070172846A1 (en) 2005-11-12 2007-07-26 Introgen Therapeutics, Inc. Methods for the Production and Purification of Adenoviral Vectors
EP1791039A1 (fr) 2005-11-25 2007-05-30 The Swatch Group Research and Development Ltd. Spiral en verre athermique pour mouvement d'horlogerie et son procédé de fabrication
DK1969127T4 (en) 2005-12-21 2017-10-16 Cnj Holdings Inc Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
AU2007234698B2 (en) 2006-04-07 2013-08-01 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US20070280906A1 (en) 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP2108045B1 (en) 2007-02-01 2013-12-11 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
KR20110005862A (ko) * 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US9249405B2 (en) 2008-09-15 2016-02-02 Paolo Simioni Factor IX polypeptide mutant, its uses and a method for its production
WO2010151736A1 (en) 2009-06-25 2010-12-29 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules
CA2769258A1 (en) 2009-07-31 2011-02-03 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
ES2764453T3 (es) 2015-03-17 2020-06-03 Univ Brussel Vrije Sistemas de expresión específica de hígado optimizados para FVIII y FIX
CN115094062A (zh) 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
CA2990193A1 (en) 2015-06-23 2016-12-29 The Children's Hospital Of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2017180861A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsulvania Gene therapy for treating hemophilia b
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
IL271957B2 (en) 2017-07-10 2024-02-01 Uniqure Ip Bv Means and methods for AAV-based gene therapy
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
EP3581650B1 (en) 2022-12-28
PL3581650T3 (pl) 2023-05-22
LTPA2024529I1 (it) 2024-12-10
HRP20181442T1 (hr) 2018-12-14
EP4032979A1 (en) 2022-07-27
HUS2400036I1 (hu) 2024-11-28
LTPA2025503I1 (it) 2025-02-10
HUE061345T2 (hu) 2023-06-28
US20220002702A1 (en) 2022-01-06
WO2010029178A1 (en) 2010-03-18
ES2985035T3 (es) 2024-11-04
US20200190498A1 (en) 2020-06-18
EP4032979C0 (en) 2024-05-01
US9982248B2 (en) 2018-05-29
EP4219547A3 (en) 2023-10-18
CA2737094A1 (en) 2010-03-18
CY1125885T1 (el) 2024-02-16
LTPA2023521I1 (it) 2023-08-25
ES2940323T3 (es) 2023-05-05
SI3581650T1 (sl) 2023-06-30
LT3581650T (lt) 2023-05-10
EP2337849A1 (en) 2011-06-29
US20200231958A1 (en) 2020-07-23
HK1244507A1 (en) 2018-08-10
US20220090042A1 (en) 2022-03-24
US20250179462A1 (en) 2025-06-05
US9249405B2 (en) 2016-02-02
DK2337849T3 (en) 2018-10-01
USRE50288E1 (en) 2025-02-04
CA2737094F (en) 2010-03-18
FIC20250007I1 (fi) 2025-01-22
HUE067487T2 (hu) 2024-10-28
DK3581650T3 (da) 2023-03-13
PL2337849T3 (pl) 2018-11-30
EP4219547A2 (en) 2023-08-02
TR201813067T4 (tr) 2018-09-21
PL4032979T3 (pl) 2024-09-30
EP4032979B1 (en) 2024-05-01
US20160122740A1 (en) 2016-05-05
NO2023029I1 (no) 2023-07-31
US20210238573A1 (en) 2021-08-05
CY2023016I2 (el) 2024-02-16
US20110244550A1 (en) 2011-10-06
FR23C1028I1 (fr) 2023-10-06
CY2023016I1 (el) 2024-02-16
US10465180B2 (en) 2019-11-05
CA2737094C (en) 2018-02-20
FIC20230026I1 (fi) 2023-07-25
HUS2300024I1 (hu) 2023-08-28
HRP20230259T1 (hr) 2023-04-28
HUS2500006I1 (hu) 2025-02-28
FR24C1040I1 (fr) 2024-12-06
EP3581650A3 (en) 2020-03-25
US20200199564A1 (en) 2020-06-25
FIC20240037I1 (fi) 2024-10-30
US20170355973A1 (en) 2017-12-14
LTPA2024530I1 (it) 2024-11-25
EP3252157A1 (en) 2017-12-06
NO2025007I1 (no) 2025-01-21
FR24C1041I1 (fr) 2024-12-06
FI3581650T3 (fi) 2023-03-23
FR25C1004I1 (fr) 2025-02-28
US20210214704A1 (en) 2021-07-15
EP2337849B1 (en) 2018-06-13
FIC20240036I1 (fi) 2024-10-29
ES2687038T3 (es) 2018-10-23
SMT202300084T1 (it) 2023-05-12
PT3581650T (pt) 2023-03-08
US20180258413A1 (en) 2018-09-13
EP3581650A2 (en) 2019-12-18
HUS2400037I1 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
HUS2500006I1 (hu) IX-es faktor polipeptid mutáns, alkalmazásai és eljárás elõállítására
ZA200908428B (en) Method for the production of a component, and component
PL2080736T3 (pl) Aerożele węglowe, sposób ich wytwarzania i ich zastosowanie
PL2350208T5 (pl) Sadza, sposób jej wytwarzania i jej zastosowanie
PL2205354T3 (pl) Sposób wytwarzania biodiesla
ZA201005599B (en) Cover and method for the production thereof
IL204555A0 (en) (carboxylalkylene-phenyl) phenyl-oxalamides, method for the production thereof, and use of same as a medicatment
EP2196534A4 (en) RECOMBINANT MICROORGANISM AND METHOD FOR PRODUCING POLY GAMMA GLUTAMINE ACID
ZA201007720B (en) Production method
EP2130909A4 (en) METHOD OF PRODUCING TOOTH AND TOOTH PRODUCED BY THE METHOD
IL207168A0 (en) Mouthpiece and method for the production thereof
PL2236610T3 (pl) Ulepszony promotor oraz sposób wytwarzania l-lizyny z jego zastosowaniem
IL233881A (en) Yeast genetically modified yeasts for squalene production, a genetically modified yeast yeast preparation and method for making them
EP2351496A4 (de) Unterhose für männer und herstellungsverfahren dafür
ZA200801281B (en) Electrolytic manganese dioxide, and method for its production and its application
ZA200901945B (en) Hydrogen production method
EP2384388A4 (en) Configurations and methods for improved subsea production control
PL2288500T3 (pl) Laminat i sposób jego wytwarzania
PL2116564T3 (pl) Absorbent i sposób jego wytwarzania
ZA201200528B (en) Novel alkoxyenones and enaminoketones and a method for the production thereof
PL2262894T3 (pl) Rekombinowany mikroorganizm i sposób wytwarzania l-lizyny
HRP20150188T1 (en) Assembly and method for paper production
EP2401446A4 (en) COMPONENT AND METHOD FOR PRODUCING THE ELEMENT
GB0822093D0 (en) Improved phospholid and method for its production
GB2452225B (en) Membrane production method